Brüggemann, M., C. Spicer, L. Buluwela, I. Rowell, S. Barton, et al.
(1991) “Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus,” Eur. J. Immunol., 21: 1323–6. Bruhns, P., B. Iannascoli, P. England, D.A. Mancardi, N. Fernandez, et al.
(2009) “Specificity and affinity of human Fcγreceptors and their polymorphic variants for human IgG subclass,” Blood, 113: 3716–25. Bruton, O.C. (1952) “Agammaglobulinemia,” Pediatrics, 9: 722–7. Bryceson, Y.T., S.C. Chiang, S. Darmanin, C. Fauriat, H. Schlums, et al.
椭圆形的东西
(2011) “Molecular mechanisms of natural killer cell activation,”
J. Innate Immun., 3: 216–26.
Brych, S.R., Y.R. Gokarn, H. Hultgen, R.J. Stevenson, R. Rajan, et al.
(2010) “Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation,” J. Pharm. Sci., 99: 764–81. Bryson, C.J., T.D. Jones, and M.P. Baker (2010) “Prediction of immunogenicity of therapeutic proteins: validity of computational tools,” BioDrugs, 24: 1–8.
Bugelski, P.J. and G. Treacy (2004) “Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans,” Curr. Opin. Mol. Ther., 6: 10–16.
描绘的近义词
Bugelski, P.J., R.J. Capocasale, D. Makropoulos, D. Marshall, P.W. Fisher, et al. (2008) “CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics in mice,” J. Biotechnol., 134: 171–80. Burge, D.J., S.A. Bookbinder, A.J. Kivitz, R.M. Fleischmann, C. Shu, et al.
(2008) “Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Pha I, open-label, do-escalation clinical study,” Clin. Therap., 30: 1806–16.
Burke, P.J., P.D. Senter, D.W. Meyer, J.B. Miyamoto, M. Anderson, et al.
(2009) “Design, synthesis, and biological evaluation of antibody-drug conjugates comprid of potent camptothecin analogues,” Bioconj.
Chem., 20: 1242–50.
Burnet, F.M. (1976) “A modification of Jerne’s theory of antibody production using the concept of clonal lection,” CA Cancer J. Clin., 26: 119–21.
Burtrum, D., Z. Zhu, D. Lu, D.M. Anderson, M. Prewitt, et al. (2003) “A fully human monoclonal antibody to the insulin-like growth factor
右佥都御史I receptor blocks ligand-dependent signaling and inhibits human tumor
growth in vivo,” Cancer Res., 63: 8912–21.
Bussiere, J.L. (2008) “Species lection considerations for preclinical toxicology studies for biotherapeutics,” Expert Opin. Drug Metab.
Toxicol., 4: 871–7.
Büttel, I.C., P. Chamberlain, Y. Chowers, F. Ehmann, A. Greinacher, et al.
(2011) “Taking immunogenicity asssment of therapeutic proteins to the next level,” Biologicals, 39: 100–9.
Byers, R.J. and E.R. Hitchman (2011) “Quantum dots brighten biological imaging,” Prog. Histochem. Cytochem., 45: 201–37.
Byrn, R.A., J. Mordenti, C. Lucas, D. Smith, S.A. Marsters, et al. (1990) “Biological properties of a CD4 immunoadhesin,” Nature, 344: 66770.
Cacciatore, J.J., L.A. Chasin, and E.F. Leonard (2010) “Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the dhfr-bad CHO cell lection system,”
Biotechnol. Adv., 28: 673–81.
Caliceti, P. and F.M. Verone (2003) “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates,” Adv. Drug Deliv. Rev., 55: 1261–77.
Camidge, D.R. (2008) ‘Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Recceptor 2 for u in the treatment of solid tumors,” Exp. Opin. Biol. Ther., 8: 1167–76.
Campath®prescribing information (2009) Genzyme Corporation, Cambridge, MA, /pdfs/2009-08-Campath%20 US%20PI.pdf (last accesd July 6, 2012).
Canfield, S.M. and S.L. Morrison (1991) “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge reg
ion,” J. Exp.
Med., 173: 1483–91.
Canatella, P.J., J.F. Karr, J.A. Petros, and M.R. Prausnitz (2001) “Quantitative study of electroporation-mediated molecular uptake and cell viability,” Biophys. J., 80: 755–64.
Cao, X., E.W. Shores, J. Hu-Li, M.R. Anver, B.L. Kelsall, et al. (1995) “Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain,” Immunity, 2: 223–38. Capala, J. and K. Bouchelouche (2010) “Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy,” Curr. Opin. Oncol., 22: 559–66.
Capon, D.J., S.M. Chamow, J. Mordenti, S.A. Marsters, T. Gregory, et al.
(1989) “Designing CD4 immunoadhesins for AIDS therapy,” Nature, 337: 525–31.
Carter, P. (2001) “Bispecific human IgG by design,” J. Immunol. Meth., 248: 7–15.
Carter, P.J. (2006) “Potent antibody therapeutics by design,” Nature Rev.
Immunol., 6: 343–57.
Carter, P.J. and L.G. Presta (1998) Immunoglobulin Variants, US Patent 5821337.
Carter, P.J. and P.D. Senter (2008) “Antibody-drug conjugates for cancer therapy,” Cancer J., 14: 154–69.
Carter, P.J., L. Presta, C.M. Gorman, J.B.B. Ridgeway, D. Henner, et al.
(1992) “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc. Nat’l. Acad. Sci. USA, 89: 4285–9.
Carton, J.M., T. Sauerwald, P. Hawley-Nelson, B. Mor, N. Peffer, et al.
(2007) “Codon engineering for improved antibody expression in mammalian cells,” Prot. Exp. Purif., 55: 279–86.
Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bordos, et al. (2002) “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene,” Blood, 99: 754–8.
Casadevall, A. (1996) “Antibody-bad therapies for emerging infectious dias,” Emerg. Infect. Dis., 2: 200–8.
Casadevall, A. (2002) “Passive antibody administration (immediate immunity) as a specific defen against biological weapons,” Emerg.
Infect. Dis., 8: 833–41.
Casadevall, A. and M.D. Scharff (1995) “Return to the past: the ca for antibody-bad therapies in infectious dias,” Clin. Infect. Dis., 21: 150–61.
Cassard, L., J.F.G. Cohen-Solal, E.M. Fournier, S. Camilleri-Broët,
A. Spatz, et al. (2008) “Selective expression of inhibitory Fcγ receptor by
metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular respon,” Internat. J. Cancer, 123: 2832–9.
Cerutti, A. and M. Rescigno (2008) “The biology of intestinal immunoglobulin A respons,” Immunity, 28: 740–50.
Cervenak, J., B. Bender, Z. Schneider, M. Magna, B.V. Carstea, et al. (2011) “Neonatal FcR overexpression boosts humoral immune respon in transgenic mice,” J. Immunol., 186: 959–68.
Chabot, G.G. (1997) “Clinical pharmacokinetics of irinotecan,” Clin.
Pharmacokin., 33: 245–59.
Chames, P. and D. Baty (2011) “Bispecific single domain antibodies,” in R.E. Kontermann (ed.), Bispecific Antibodies. Berlin: Springer, pp. 101–14.
Chamow, S.M., A.M. Duliege, A. Ammann, J.O. Kahn, J.D. Allen, et al.
(1992) “CD4 immunoadhesins in anti-HIV therapy: new developments,”
Internat. J. Cancer Suppl., 7: 69–72.
Chan, A.C. and P.J. Carter (2010) “Therapeutic antibodies for autoimmunity and inflammation,” Nature Rev. Immunol., 10: 301–16. Chantalat, L., N.D. Jones, F. Korber, J. Navaza, and A.G. Pavlovsky (1995) “The crystal-structure of wild-type growth-hormone at 2.5 angstrom resolution,” Protein Pept. Lett., 2: 333–40.
Chao, G., J.R. Cochran, and K.D. Wittrup (2004) “Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display,” J. Mol. Biol., 342:
539–50. Chapman, K., N. Pullen, M. Graham, and I. Ragan (2007) “Preclinical safety testing of monoclonal antibodies: the significance of species relevance,” Nature Rev. Drug Disc., 6: 120–6.
Chapman, A.P., P. Antoniw, M. Spitali, S. West, S. Stephens, and D.J. King (1999) “Therapeutic antibody fragments with prolonged in vivo half-lives,” Nature Biotechnol., 17: 780–3.
百合花英文
Chappel, M.S., D.E. Inman, M. Everett, Y.-Y. Xu, K.J. Dorrington, et al.
(1991) “Identification of the Fcγclass I binding site in human IgG through the u of recombinant IgG1/IgG2 hybrid and point mutated antibodies,” Proc. Nat’l. Acad. Sci. USA, 88: 9036–40.
Chappel, M.S., D.E. Inman, R. Oomen, T.T. Xu, and M.L. Klein (1993) “Identification of a condary FcγRI binding site with a genetically engineered human IgG1 antibody,” J. Biol. Chem., 268: 25124–31. Chari, R.V.J. (2008) “Targeted cancer therapy: conferring specificity to cytotoxic drugs,” Acc. Chem. Res., 41: 98–107.
Chari, R.V.J., B.A. Martell, J.L. Gross, S.B. Cook, S.A. Shah, et al. (1992) “Immunoconjugates containing novel maytansinoids: promising anticancer drugs,” Cancer Res., 52: 127–31.
Chartrain, M. and L. Chu (2008) “Development and production of commercial therapeutic monoclona
l antibodies in mammalian cell expression systems: an overview of the current upstream technologies,”
Curr. Pharm. Biotechnol., 9: 447–67.
Chatenoud, L., C. Ferran, C. Legendre, I. Thouard, S. Merite, et al. (1990) “In vivo cell activation following OKT3 administration. Systemic cytokine relea and modulation by corticosteroids,” Transplantation, 49: 697–702. Chaudhri, O., C. Small, and S. Bloom (2006) “Gastrointestinal hormones regulating appetite,” Phil. Trans. R. Soc. B., 361: 1187–209. Chaudhury, C., S. Mehnaz, J.M. Robinson, W.L. Hayton, D.K. Peral, et al.
(2003) “The major histocompatability complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan,” J. Exp. Med., 197: 315–22.
Chaudhury, C., C.L. Brooks, D.C. Carter, J.M. Robinson, and C.L.
Anderson (2006) “Albumin binding to FcRn: distinct from the FcRn-IgG interaction,” Biochemistry, 45: 4983–90.
梦见发大洪水
Chelius, D., D.S. Rehder, and P.V. Bondarenko (2005) “Identification and characterization of deamid
ation sites in the conrved regions of human immunoglobulin gamma antibodies,” Analyt. Chem., 77: 6004–11. Chelius, D., K. Jing, A. Lueras, D.S. Rehder, T.M. Killon, et al. (2006) “Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies,” Analyt. Chem., 78: 2370–6. Chen, K.-C., S.-Y. Wu, Y.-L. Leu, Z.M. Prijovich, B.-M. Chen, et al.
埃德加爱伦坡(2011a) “A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment,”
遮掩的意思Bioconj. Chem., 22: 938–48.
Chen, W., Z. Zhu, Y. Feng, and D.S. Dimitrov (2010) “A large human domain antibody library combining heavy and light chain CDR3 diversity,” Mol. Immunol., 47: 912–21.
Chen, X., Y.D. Liu, and G.C. Flynn (2009) “The effect of Fc glycan forms on human IgG2 antibody clearance in humans,” Glycobiol., 19: 240–9. Chen, Y., Y. Zhang, Y. Yin, G. Gao, S. Li, et al. (2005) “SPD – a web-bad creted protein databa,” Nucl. Acids Res., 33 (databa issue): D169–D173.
Chen, Z., K. Chumakov, E. Dargunsky, D. Kouiavskaia, M. Makiya, et al.
(2011b) “Chimpanzee/human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency post-exposure prophylaxis,”
J. Virol., 85: 4354–62.
贸易制裁
Chen, Z., M. Moayeri, Y.H. Zhou, S. Leppla, S. Emerson, et al. (2006) “Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen,” J. Infect. Dis., 193: 625–33.
